The amplification of TPX2 is a potential biomarker of oxaliplatin-sensitivity of colorectal cancers (CRCs) with CIN phenotype

被引：0
|
作者：
Ueno, Shohei
Isobe, Taichi
Taguchi, Ryosuke
Tsuchihashi, Kenji
Akashi, Koichi
Baba, Eishi
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-2517
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2517
引用
收藏
页数：2
相关论文
共 12 条
  • [1] TPX2-amplified is a biomarker of oxaliplatin-sensitivity of colorectal cancers (CRCs) with CIN phenotype
    Ueno, Shohei
    Isobe, Taichi
    Taguchi, Ryosuke
    Tsuchihashi, Kenji
    Akashi, Koichi
    Baba, Eishi
    CANCER SCIENCE, 2024, 115 : 487 - 487
  • [2] Colorectal cancers (CRCs) with TPX2 amplification is highly sensitive to oxaliplatin
    Ueno, Shohei
    Isobe, Taichi
    Taguchi, Ryosuke
    Yamaguchi, Kyoko
    Tsuchihashi, Kenji
    Akashi, Koichi
    Baba, Eishi
    CANCER SCIENCE, 2025, 116 : 1882 - 1882
  • [3] The amplification of TPX2 is a potential biomarker of oxaliplatin-susceptibility in colorectal cancer
    Ueno, Shohei
    Isobe, Taichi
    Taguchi, Ryosuke
    Tsuchihashi, Kenji
    Ariyama, Hiroshi
    Akashi, Koichi
    Baba, Eishi
    CANCER SCIENCE, 2023, 114 : 1449 - 1449
  • [4] Matrix metalloproteinases (MMPs) in chromosomally unstable (CIN) colorectal cancers (CRCs) may mediate the invasive potential
    Kashiwagi, K
    Goel, A
    Boland, CR
    GASTROENTEROLOGY, 2004, 126 (04) : A389 - A389
  • [5] S100A10 as a potential protein biomarker for oxaliplatin sensitivity in colorectal cancer cells
    Suzuki, Sayo
    Yamayoshi, Yasuko
    Nishimuta, Akito
    Watanabe, Mitsuhiro
    Tanigawara, Yusuke
    CANCER RESEARCH, 2009, 69
  • [6] FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers
    Cha, Yongjun
    Kim, Hwang-Phill
    Han, Sae-Won
    Yun, Jiyeon
    Song, Sang-Hyun
    Kim, Tae-You
    CANCER RESEARCH, 2015, 75
  • [7] FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro
    Cha, Yongjun
    Kim, Hwang-Phill
    Lim, Yoojoo
    Han, Sae-Won
    Song, Sang-Hyun
    Kim, Tae-You
    MOLECULAR ONCOLOGY, 2018, 12 (07): : 993 - 1003
  • [8] PKM2 as a biomarker for sensitivity to oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC).
    Papadaki, C.
    Saridaki, Z.
    Tzardi, M.
    Sfakianaki, M.
    Sfakiotaki, G.
    Trypaki, M.
    Messaritakis, I.
    Mavroudis, D.
    Georgoulias, V.
    Sougklakos, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [9] CDX2 Expression as a Potential Surrogate Marker for CpG Island Methylator Phenotype in Colorectal Cancers
    Zlobec, I.
    Bihl, M.
    Foerster, A.
    Rufle, A.
    Lugli, A.
    LABORATORY INVESTIGATION, 2011, 91 : 175A - 175A
  • [10] CDX2 Expression as a Potential Surrogate Marker for CpG Island Methylator Phenotype in Colorectal Cancers.
    Zlobec, I.
    Bihl, M.
    Foerster, A.
    Rufle, A.
    Lugli, A.
    MODERN PATHOLOGY, 2011, 24 : 175A - 175A
12